Cite
Abstract No. 210 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation
MLA
U. Malhotra, et al. “Abstract No. 210 KEYNOTE-937 Trial in Progress: Adjuvant Pembrolizumab for Hepatocellular Carcinoma and Complete Radiologic Response after Surgical Resection or Local Ablation.” Journal of Vascular and Interventional Radiology, vol. 32, May 2021, pp. S92–93. EBSCOhost, https://doi.org/10.1016/j.jvir.2021.03.216.
APA
U. Malhotra, Andrew X. Zhu, J. Zhou, Masatoshi Kudo, A. Cheng, Thomas Yau, Abby B. Siegel, Arndt Vogel, & Eunhee Kim. (2021). Abstract No. 210 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation. Journal of Vascular and Interventional Radiology, 32, S92–S93. https://doi.org/10.1016/j.jvir.2021.03.216
Chicago
U. Malhotra, Andrew X. Zhu, J. Zhou, Masatoshi Kudo, A. Cheng, Thomas Yau, Abby B. Siegel, Arndt Vogel, and Eunhee Kim. 2021. “Abstract No. 210 KEYNOTE-937 Trial in Progress: Adjuvant Pembrolizumab for Hepatocellular Carcinoma and Complete Radiologic Response after Surgical Resection or Local Ablation.” Journal of Vascular and Interventional Radiology 32 (May): S92–93. doi:10.1016/j.jvir.2021.03.216.